FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Dowell

Research Profile

Concepts & Ideas

Chemicals & Drugs

Phenomena

Procedures

Physiology

Drug Interactions

Disorders

Soft Tissue Infections

Co-author Network

Publications

TOP 3
David P Nicolau; Heather K Sun; Elyse Seltzer; Mary Buckwalter; James A Dowell
Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
Eric Solon; James A Dowell; Jonghui Lee; S Peter King; Bharat D Damle
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
James A Dowell; Martin Stogniew; David Krause; Bharat D Damle
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Dowell (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: David P Nicolau; Heather K Sun; Elyse Seltzer; Mary Buckwalter; James A Dowell
Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
The Journal of antimicrobial chemotherapy 2007;60(3):681-4.
2007: Eric Solon; James A Dowell; Jonghui Lee; S Peter King; Bharat D Damle
Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits.
Antimicrobial agents and chemotherapy 2007;51(8):3008-10.
2007: James A Dowell; Martin Stogniew; David Krause; Bharat D Damle
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.
Journal of clinical pharmacology 2007;47(4):461-70.
2007: James A Dowell; Martin Stogniew; David Krause; Timothy Henkel; Bharat D Damle
Lack of pharmacokinetic interaction between anidulafungin and tacrolimus.
Journal of clinical pharmacology 2007;47(3):305-14.
2006: Daniel K Benjamin; Timothy A Driscoll; Nita L Seibel; Corina Gonzalez; Maureen M Roden; Rakhi Kilaru; Kay Clark; James A Dowell; Jennifer Schranz; THOMAS WALSH
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections.
Antimicrobial agents and chemotherapy 2006;50(2):632-8.
2005: James A Dowell; Jennifer Schranz; Alice Baruch; Grover Foster
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
Journal of clinical pharmacology 2005;45(12):1373-82.
2005: Mary Buckwalter; James A Dowell
Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide.
Journal of clinical pharmacology 2005;45(11):1279-87.
2005: James A Dowell; Martin Stogniew; David Krause; Timothy Henkel; Irving E Weston
Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
Journal of clinical pharmacology 2005;45(2):227-33.
2004: Mary Buckwalter; James A Dowell; Joan Korth-Bradley; boris gorovits; Philip R Mayer
Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
Journal of clinical pharmacology 2004;44(8):873-80.
2004: James A Dowell; William Knebel; Tom Ludden; Martin Stogniew; David Krause; Timothy Henkel
Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.
Journal of clinical pharmacology 2004;44(6):590-8.
2003: Elyse Seltzer; Mary Beth Dorr; Beth P Goldstein; Marc Perry; James A Dowell; Timothy Henkel
Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2003;37(10):1298-303.
2002: Mark S Berger; Lance H Leopold; James A Dowell; Joan Korth-Bradley; Matthew L Sherman
Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse.
Investigational new drugs 2002;20(4):395-406.
2001: James A Dowell; Joan Korth-Bradley; H Liu; S Peter King; Mark S Berger
Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse.
Journal of clinical pharmacology 2001;41(11):1206-14.
2001: Joan Korth-Bradley; James A Dowell; S Peter King; H Liu; Mark S Berger
Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin.
Pharmacotherapy 2001;21(10):1175-80.
2001: James A Dowell; Joan Korth-Bradley; M Milisci; K Tantillo; P Amorusi; S Tse
Evaluating possible pharmacokinetic interactions between tobramycin, piperacillin, and a combination of piperacillin and tazobactam in patients with various degrees of renal impairment.
Journal of clinical pharmacology 2001;41(9):979-86.